Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation

Bijay S. Jaiswal, Vasantharajan Janakiraman, Noelyn M. Kljavin, Subhra Chaudhuri, Howard M. Stern, Weiru Wang, Zhengyan Kan, Hashem A. Dbouk, Brock A. Peters, Paul Waring, Trisha Dela Vega, Denise M. Kenski, Krista K. Bowman, Maria Lorenzo, Hong Li, Jiansheng Wu, Zora Modrusan, Jeremy Stinson, Michael Eby, Peng YueJosh S. Kaminker, Frederic J. de Sauvage, Jonathan M. Backer, Somasekar Seshagiri

Research output: Contribution to journalArticlepeer-review

250 Scopus citations


Members of the mammalian phosphoinositide-3-OH kinase (PI3K) family of proteins are critical regulators of various cellular process including cell survival, growth, proliferation, and motility. Oncogenic activating mutations in the p110α catalytic subunit of the heterodimeric p110/p85 PI3K enzyme are frequent in human cancers. Here we show the presence of frequent mutations in p85α in colon cancer, a majority of which occurs in the inter-Src homology-2 (iSH2) domain. These mutations uncouple and retain p85α's p110-stabilizing activity, while abrogating its p110-inhibitory activity. The p85α mutants promote cell survival, AKT activation, anchorage-independent cell growth, and oncogenesis in a p110-dependent manner.

Original languageEnglish (US)
Pages (from-to)463-474
Number of pages12
JournalCancer Cell
Issue number6
StatePublished - Dec 8 2009



ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research


Dive into the research topics of 'Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation'. Together they form a unique fingerprint.

Cite this